PTAB ARP Issues Precedential Decision on Obviousness-Type Double Patenting, Asks CAFC for More Clarity

An Appeals Review Panel (ARP) of the U.S. Patent and Trademark Office’s (USPTO’s ) Patent Trial and Appeal Board (PTAB) today issued a decision on sua sponte rehearing reversing a PTAB decision that had itself reversed an examiner’s rejection of claims for obviousness-type double patenting (OTDP). The decision has been designated as precedential and was authored by USPTO Director John A. Squires, PTAB Chief Judge Kalyan Deshpande, and PTAB Acting Deputy Chief Judge Michelle Ankenbrand.

USPTO Policy On Discretion to Deny Ex Parte Reexamination Is Contrary to Statute and Precedent

As the institution rate of inter partes reviews (IPRs) has plunged under U.S. Patent and Trademark Office (USPTO) Director John Squires, parties have increasingly turned to ex parte reexaminations (EPRs) to challenge patents. The number of requests for EPRs has skyrocketed. The number of EPR requests more than doubled between 2020 (198 requests) and 2025 (481 requests). See USPTO Reexam Statistics. Based on the number of requests for EPRs (831) assigned a filing date through Q3 of 2026, we are on track to have more than 1,100 requests for EPRs filed in FY2026. See USPTO Operational Statistics.

Issa Introduces Bill to Name Main CAFC Courtroom after Judge Pauline Newman

Representative Darrell Issa (R-CA), Chairman of the Subcommittee on Intellectual Property, Artificial Intelligence, and the Internet, has introduced a bill to designate courtroom 201 at the Howard T. Markey National Courts Building located at 717 Madison Place NW, Washington, DC, as the “Pauline Newman Courtroom”. Room 201 is the main courtroom of the U.S. Court of Appeals for the Federal Circuit (CAFC).

The Patent Enforcement Economy Is Leaving Inventors Behind/ IPWatchdog Unleashed

The patent system makes a promise that has become increasingly conditional. An inventor discloses an invention to the public and, in return, receives a limited right to exclude. On paper, that bargain remains intact. In the real world, however, a patent owner often discovers that functionally the right is only defensible if the infringement is large enough (but not too large), the damages are high enough (but not too high), the portfolio is deep enough, and somebody is willing to finance years of litigation. Our conversation this week for IPWatchdog Unleashed is about what happens after a patent owner has completed the tedious work of understanding what is actually owned and is now ready to pursue a licensing or enforcement campaign.

Nike Loses to Lululemon in CAFC Appeal of PTAB Decision Invalidating Adaptive Watch Patent Claims

The U.S. Court of Appeals for the Federal Circuit (CAFC) on Wednesday issued an opinion authored by Chief District Judge Cathy Bissoon of the U.S. District Court for the Western District of Pennsylvania, sitting by designation, affirming a Patent Trial and Appeal Board (PTAB) decision that Lululemon had shown the challenged claims of Nike, Inc.’s patent to be unpatentable.

Ninth Circuit Again Reverses Jack Daniel’s Trademark Win Due to Bad Spaniels’ Successful Parody

On Tuesday, the U.S. Court of Appeals for the Ninth Circuit issued a published ruling reversing the U.S. District Court for the District of Arizona’s entry of permanent injunction for distiller Jack Daniel’s in the long-running trademark case involving VIP Products’ Bad Spaniels dog toy. This latest chapter in the decade-plus-long case remands the decision back to the district court with orders to enter judgment in favor of defendant VIP Products after finding that Jack Daniel’s did not meet its burden to show dilution by tarnishment.

Federal Circuit Affirms Non-Infringement Ruling in Lidocaine Patch Patent Dispute Over ZTlido Generic

The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a decision Tuesday affirming a judgment of non-infringement entered by the U.S. District Court for the Southern District of Florida in a dispute concerning generic versions of the topical pain patch ZTlido. The panel of Judges Reyna, Mayer, and Hughes, ruling per curiam, upheld the district court’s construction of the term “dissolving agent” and its determination that Aveva Drug Delivery Systems’ proposed generic product did not infringe under the doctrine of equivalents.

Varsity Sponsors

From the IPWatchdog Institute

Subscribe to IPWatchdog

This is the best way to stay informed. We send a daily roundup of our latest news, press releases, and events.

Get Email Updates